By using our site you accept the terms of our cookie policy

Search

EVOTEC RECEIVES $ 23.8 M GRANT TO JOIN THE GLOBAL FIGHT AGAINST TUBERCULOSIS

July 4, 2019

Image

THE BILL & MELINDA GATES FOUNDATION SUPPORTS EVOTEC WITH A $ 23.8 M GRANT TO GENERATE CRITICAL DATA FOR SELECTING BEST DRUG COMBINATIONS FOR PHASE II CLINICAL TRIALS


TUBERCULOSIS IS THE LEADING CAUSE OF DEATH DUE TO AN INFECTIOUS DISEASE WORLDWIDE 


FIVE-YEAR PARTNERSHIP IS FOCUSED ON EVALUATING NEW TREATMENT REGIMENS THAT CAN SUBSTANTIALLY REDUCE TREATMENT TIME AND OVERCOME RESISTANCE TO CURRENT THERAPIES

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ("TB"), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.

Evotec will receive a grant of approximately $ 23.8 m for a period of up to 5 years from the foundation. The main objective of the grant is to generate standardised, high-quality pre-clinical data to support novel regimen selection and development. The regimen should be safer, shorter in duration and more efficacious than the current standard of care. With this new grant from the Bill & Melinda Gates Foundation, Evotec has been selected once more as an essential partner for charities and foundations, such as CHDI, The Michael J. Fox Foundation and the Mark Foundation, in their research and development efforts to address complex, rare and difficult diseases.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are honoured to join with The Bill & Melinda Gates Foundation to fight tuberculosis, one of the world's most deadly infectious diseases. With our contributions of industrialised, high quality infrastructure and innovative methodology, we are confident that this combined international effort is the best possible starting point to bring huge benefits to the large number of patients who suffer from TB around the globe."

Contact Us

+44 (0) 203 725 6847